Skip to content
Matterworks logo — AI for the Language of Biochemistry

Matterworks

AI for the Language of Biochemistry

Founded 2019 United States Somerville, United States 32 employees Seed Total: $13.75M AI, Biotechnology +1

General Information

Company Name Matterworks
Founded Year 2019
Location United States Somerville, United States
Employees 32
Industries AI, Biotechnology, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Matterworks. To contact Matterworks, visit matterworks.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Matterworks compare?

A PDF of Matterworks and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Matterworks soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Matterworks

Matterworks is a United States-based startup founded in 2019 with the slogan "AI for the Language of Biochemistry." The company operates in the AI, Biotechnology, and Pharmaceutical industries, leveraging AI to revolutionize the impact of biological measurements and observations. In a significant development, Matterworks secured a $7.50M investment in a Seed Round on 14 August 2023, with Germin8 Ventures stepping in as the investor. This investment underscores the growing interest and confidence in Matterworks' innovative approach, positioning the company for potentially transformative advancements in the intersection of AI and biochemistry.

Business keywords: AI-powered tools, metabolomics, analytical chemistry, therapeutic research, drug development, biological engineering, AI applications, biomedical technology

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $7.50M 1
Germin8 Ventures
14 Aug 2023
Convertible Note Undisclosed 1
Tarsadia Investments
01 Jan 2023
Seed Round $6.00M 5
Pillar, Wing VC +3
17 Dec 2020
Pre Seed Round $250.00K 1
Petri
01 Nov 2019

Matterworks Alternatives & Competitors

View All Alternatives
Matterworks vs

Crafting innovative treatments rooted in over a decade of research into inflammatory diseases.

Venture round
2 employees
Biotechnology, Pharmaceutical
Matterworks vs
Elicio Therapeutics
Elicio Therapeutics United States

Lymph-Node Targeted Immunotherapies

IPO
47 employees
Biotechnology, Health Care
Matterworks vs
Enable Medicine
Enable Medicine United States

Spatial and multimodal insights powered by AI for your next therapeutic breakthrough.

Acquired
15 employees
Biotechnology, Pharmaceutical

FAQ About Matterworks

AI for the Language of Biochemistry
Matterworks was founded in 2019.
Matterworks is headquartered in Somerville, United States.
Matterworks operates in AI, Biotechnology and Pharmaceutical. Its work centres on AI-powered tools, metabolomics, analytical chemistry and therapeutic research.
Matterworks has approximately 32 employees.
Matterworks has completed 4 funding rounds, raising a total of $13.75M. The latest funding stage is Seed.
Top alternatives and competitors to Matterworks include Avexxin, Elicio Therapeutics, Enable Medicine, Seven Bridges, Vilya. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Matterworks and Avexxin are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Matterworks, https://bouncewatch.com/company/matterworks-1, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout